Revumenib Shows Promise for Advanced Acute Myeloid Leukemia - NCI

In the AUGMENT-101 trial, treatment with revumenib caused complete remission in about one-third of participants, all of whom had many prior treatments. The targeted therapy is part of a new class of drugs known as menin inhibitors.

Heather LaGrande on LinkedIn: Pembrolizumab for Advanced Triple

May 15 2012 - The ASCO Post

Al Giovanniello on LinkedIn: Revumenib Shows Promise for Advanced

Treatment National Cancer Institute

Revumenib: a new therapy for AML patients

National Cancer Institute (NCI) on LinkedIn: Cancer Grand

Treatment National Cancer Institute

Clinical Trial Results - Cancer Currents Blog - NCI

Contemporary Approach to Acute Myeloid Leukemia Therapy in 2022

Transforming NCI Cancer Clinical Trials - NCI

Clinical Trial Results National Cancer Institute

Namrata Gautam on LinkedIn: Signals released from dying cancer